人民财讯1月9日电，贝达药业(300558)1月9日公告，近日，公司已与花园集团完成股权转让交割，公司 出资5000万元受让花园集团持有的杭州知兴制药有限公司（简称"知兴制药"）注册资本200万元，投后 总占比为20%。知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚，已搭建完善的研发与 生产体系，具备将产品从实验室到产业化落地的能力。目前，其在研产品管线中适用于哮喘、COPD等 适应症的三款产品：丙酸氟替卡松雾化吸入用混悬液、吸入用丙酸倍氯米松混悬液及沙美特罗普卡松吸 入粉雾剂均已完成生物等效性（BE）试验，其中丙酸氟替卡松雾化吸入用混悬液申报上市在即。 转自：证券时报 ...

Core Viewpoint - Beida Pharmaceutical has completed the equity transfer with Huayuan Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical for 50 million yuan, which will enhance its new drug development technology platform and expand its strategic layout in disease treatment [1] Group 1 - Beida Pharmaceutical invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [1] - Zhixing Pharmaceutical focuses on the development of high-end inhalation formulations and has established a comprehensive R&D and production system [1] - The investment does not constitute a related party transaction or a major asset restructuring, and does not require approval from relevant authorities [1] Group 2 - This investment will help Beida Pharmaceutical to broaden its strategic layout in the field of disease treatment [1]

贝达药业公告，公司出资5000万元人民币受让花园集团持有的杭州知兴制药有限公司注册资本人民币 200万元，投后总占比为20%。 ...

证券代码：300558 证券简称：贝达药业 公告编号：2026-001 贝达药业股份有限公司 关于投资杭州知兴制药有限公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 为进一步发挥贝达药业股份有限公司（以下简称"贝达药业"或"公司"）在 生物医药领域的产业优势，围绕高壁垒技术领域持续完善生态圈布局，近日，公司 已与花园集团有限公司（以下简称"花园集团"）完成股权转让交割，公司出资 5,000 万元人民币受让花园集团持有的杭州知兴制药有限公司（以下简称"知兴制 药"或"标的公司"）注册资本人民币 200 万元，投后总占比为 20%（以下简称 "本次投资"）。知兴制药专注于高端吸入制剂开发，核心技术人员行业背景深厚， 已搭建完善的研发与生产体系，具备将产品从实验室到产业化落地的能力。 根据《深圳证券交易所创业板股票上市规则》（以下简称"《上市规则》"）、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交易》等法律法规、 规范性文件及《贝达药业股份有 ...

Core Viewpoint - Benda Pharmaceutical's stock has shown a mixed performance with a year-to-date increase of 7.90%, but a significant decline of 12.97% over the past 60 days, indicating volatility in its market position [1]. Financial Performance - For the period from January to September 2025, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 669 million yuan, with 184 million yuan distributed over the past three years [3]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - The stock's trading activity showed a net outflow of 9.349 million yuan from major funds, with significant buying and selling activity from large orders [1]. Company Overview - Benda Pharmaceutical, established on January 7, 2003, and listed on November 7, 2016, is primarily engaged in the research, production, and sales of pharmaceuticals, with 99.10% of its revenue coming from drug sales [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concepts such as ophthalmology, innovative drugs, and precision medicine [1].

责任编辑：小浪快报 1月6日，贝达药业涨0.92%，成交额3.32亿元。两融数据显示，当日贝达药业获融资买入额3270.93万 元，融资偿还3332.09万元，融资净买入-61.16万元。截至1月6日，贝达药业融资融券余额合计7.00亿 元。 截至9月30日，贝达药业股东户数2.95万，较上期减少7.99%；人均流通股14198股，较上期增加8.68%。 2025年1月-9月，贝达药业实现营业收入27.17亿元，同比增长15.90%；归母净利润3.17亿元，同比减少 23.86%。 分红方面，贝达药业A股上市后累计派现6.69亿元。近三年，累计派现1.84亿元。 机构持仓方面，截止2025年9月30日，贝达药业十大流通股东中，兴全商业模式混合(LOF)A（163415） 位居第五大流通股东，持股582.70万股，为新进股东。易方达创业板ETF（159915）位居第六大流通股 东，持股545.55万股，相比上期减少91.23万股。兴全合润混合A（163406）位居第七大流通股东，持股 540.17万股，为新进股东。中欧医疗健康混合A（003095）、南方中证500ETF（510500）退出十大流通 股东之列。 ...

证券日报网讯1月6日，贝达药业（300558）在互动平台回答投资者提问时表示，公司一贯遵循法律法规 及交易所规则，对于应当披露事项的进展情况及时履行披露义务。根据实际业务开展的需要，公司推进 BPI-572270项目的临床申报工作，完成的工作节点均不属于公司法定披露的时点。目前，项目的临床申 请正在审核当中，如有重大进展，公司会及时公告披露。 ...

证券日报网讯1月6日，贝达药业（300558）在互动平台回答投资者提问时表示，杭州景曜生物科技有限 责任公司自2025年10月成立后尚未进行实际业务的开展，公司受让股权除了承担该公司的注册资本出资 责任外，未支付其他费用。 ...

证券日报网讯1月6日，贝达药业（300558）在互动平台回答投资者提问时表示，公司已按工作业务的相 关进展预约2026年4月23日为2025年年度报告披露日。目前公司经营正常，2025年经营业绩相关信息请 以公司公开披露为准。 ...

Policy Developments - The State Council approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely revisions to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Industry Initiatives - Hainan Province aims to develop over six distinctive traditional Chinese medicine health tourism routes by the end of 2028, with a target of cultivating over 1 million mu of medicinal herb planting and breeding areas, and achieving a 15% growth in the overall output value of traditional Chinese medicine [2] Drug and Medical Device Approvals - Xingqi Eye Medicine announced the approval of its atropine sulfate eye drops for children aged 6 to 12, with new product specifications added [1] Capital Market Activities - Sinovac Biotech has repurchased approximately 1.32 million shares, accounting for 0.66% of its total share capital, with a total expenditure of approximately RMB 49.24 million [3] - Dongcheng Pharmaceutical plans to repurchase shares worth between RMB 100 million and RMB 200 million for employee stock ownership plans, with a maximum repurchase price of RMB 18.00 per share [4] - Haizheng Pharmaceutical's major shareholder intends to transfer 6.06% of the company's shares through a public solicitation, pending approval from relevant authorities [5] Strategic Collaborations - Sinopharm Holdings and Betta Pharmaceuticals have signed a strategic cooperation agreement to enhance collaboration and create a new efficient pharmaceutical supply chain ecosystem [6] Personnel Changes - The independent director of Nanxin Pharmaceutical, Shen Yunqiao, has resigned for personal reasons, and will continue to fulfill his duties until a new independent director is elected [7]